Baylor College of Medicine has disclosed new neurotrophic receptor tyrosine kinase (NTRK) inhibitors that are reported to be useful for the treatment of cancer, endometriosis, female infertility, pelvic pain and inflammatory disorders.
Anadolu University and Atatürk University have jointly described novel 3,5-disubstituted-1,2,4-oxadiazole derived compounds acting as carbonic anhydrase type I and/or type II inhibitors.
Imidazotriazine derivatives acting as interleukin-17 (IL-17) modulators have been described in a UCB SA patent and are reported to be potentially useful for the treatment of inflammatory disorders and autoimmune diseases.
A Sanofi SA patent describes imidazopyridine compounds acting as mitogen-activated protein kinase 7 (MAPK7; ERK5) inhibitors and reported to be useful for the treatment of cancer.
Researchers from the Academic Medical Center (AMC) University of Amsterdam are seeking protection for their invention of a total artificial heart which is compact, durable and mimics the natural movement of human tissue.
Genescience Pharmaceuticals Co. Ltd. has described cannabinoid CB2 receptor agonists reported to be useful for the treatment of arthritis, systemic lupus erythematosus, inflammatory bowel disease, allergic contact dermatitis, colitis, autoimmune diseases and pain.
Shanghai Sinotau Biotech Co. Ltd. has identified tyrosine-protein phosphatase non-receptor type 13 (PTPN13; FAP-1; PTP-1E) inhibitors reported to be useful for the treatment of cancer.
RSS
